← Back to catalogue
PSAP (Prostate Specific Acid Phosphatase) +1 more model
EUDAMEDClass C (EU MDR)
Ref A00041-0025Ref A00041-0007
Identity
- Trade Name
- PSAP (Prostate Specific Acid Phosphatase); Clone PASE/4LJ (Ready-To-Use) 25 mL EUDAMEDPSAP (Prostate Specific Acid Phosphatase); Clone PASE/4LJ (Ready-To-Use) 7 mL EUDAMED
- Device Name
- Primary Antisera for Immunohistology EUDAMED
- Model / Reference
- A00041-0025 EUDAMEDA00041-0007 EUDAMED
Identifiers
- Primary DI / UDI-DI
- 00810108710523 EUDAMED00810108710516 EUDAMED
- Basic UDI-DI
- 081010871W01030709FJ EUDAMED
- Direct Marketing DI
- 00810108710523 EUDAMED00810108710516 EUDAMED
- EMDN Code
- W01030709 PRIMARY ANTISERA FOR IMMUNOHISTOLOGY EUDAMED
- Models / Variants
Classification
- Device Class
- Class C EUDAMED
- Market of Registration
- Netherlands EUDAMED
Clinical & Handling
Sterile
No
EUDAMED
Human Tissues
No
EUDAMED
Animal Tissues
Yes
EUDAMED
Microbial Substances
No
EUDAMED
Reagent
Yes
EUDAMED
Self Testing
No
EUDAMED
Near-Patient Testing
No
EUDAMED
Professional Testing
Yes
EUDAMED
Companion Diagnostics
No
EUDAMED
Surgical Instrument
No
EUDAMED
New Device
No
EUDAMED
PSAP (Prostate Specific Acid Phosphatase) +1 more model by ScyTek Laboratories Inc. — Class C — IVDR — listed in EUDAMED — 2 models
Manufacturer's product page: Actin, Muscle Specific; Clone HHF35 SKU: A00001 Antibodies, Monoclonal
Authorization Coverage (European Union — 27 member states)
Regulatory Authorizations
European Union Active
CE/IVDR
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| EUDAMED | European Union | CE/IVDR | 081010871W01030709FJ | Class C | Active |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- ScyTek Laboratories Inc.
- EUDAMED SRN
- US-MF-000023816
- Authorised Representative
- Emergo Europe B.V. NL-AR-000000116
Sources (2)
- EUDAMED e0a5c72b-2838-4f02-a8b8-f3530812642a 61 fields · synced Jul 17, 2026
- EUDAMED f26cf19e-7e90-4f77-8091-96f9a2d18849 61 fields · synced May 18, 2026